Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04713137
Other study ID # PolyFoodIntake
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 5, 2021
Est. completion date June 3, 2021

Study information

Verified date December 2021
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this project is to investigate the effect of erythritol (given as pre-load), compared to sucrose, sucralose, and water on energy intake during a subsequent ad libitum test meal in healthy participants. Furthermore, the release of GI hormones, glycemic control, appetite-related sensations, GI tolerance, sweetness and liking in response to the pre-loads will be investigated.


Description:

The subjects will participate in four study days. The screening will last 60 minutes, the study days about 4.5 hours each. After a simple-carbohydrate standard dinner, the subjects have to do an overnight fast until the next morning. Subjects will receive fixed equisweet doses of sucrose (33.5g), erythritol (50g), sucralose (0.0558g), or water as oral pre-loads in a blinded, randomized (counterbalanced) fashion (t = -15 min). Fifteen minutes after the administration (t = 0 min), a standard solid test meal will be presented and ad libitum calorie intake will be measured. The end of the test meal will be after 20 minutes or as soon as the subject stops eating for more than 5 minutes. Blood samples (to measure: glycemic control and GI hormones) will be collected at t = -16, t = -1, t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 min and appetite-related sensation rating will be collected at t = -16, t = -1, t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 min. GI symptoms and nausea are assessed at t = -16, -1, 30, 60, 120 and 180 min. At t = -10 min subjects are asked to rate the perceived sweetness and liking of the pre-load and at t = 180 min the perceived liking of the test meal.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date June 3, 2021
Est. primary completion date June 3, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Healthy normal weight subjects with a body-mass index of 19.0-24.9 - Normal eating habits (eating breakfast; no diets; no dietary changes; no vegetarians/vegans, no intolerances/allergies) - Age 18-55 years - Stable body weight (+/- 5%) for at least three months - Informed Consent as documented by signature (Appendix Informed Consent Form) Exclusion Criteria: - Shift worker - Fructose intolerance - Pre-existing consumption of erythritol and/or sucralose more than once a week - Substance abuse - Regular intake of medications, except anticontraceptive - Chronic or clinically relevant acute infections - Pregnancy: although no contraindication, pregnancy might influence metabolic state. Women who are pregnant or have the intention to become pregnant during the course of the study are excluded. Female participants of childbearing age have to use safe contraception (oral, injectable, or implantable contraceptives, intrauterine contraceptive devices, or tubectomy). In female participants a urine pregnancy test is carried out upon screening. - Participation in another study with investigational drug within the 30 days preceding and during the present study.

Study Design


Intervention

Dietary Supplement:
Erythritol
50g erythritol dissolved in 300mL tap water.
Sucrose
33.5g sucrose dissolved in 300mL tap water.
Sucralose
0.0558g sucralose dissolved in 300mL tap water.
Water
300mL tap water.

Locations

Country Name City State
Switzerland St. Claraspital Basel

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of erythritol on energy intake during a subsequent ad libitum test meal Fifteen minutes after the administration of the pre-loads (t = 0 minutes), a standard solid test meal will be presented and ad libitum calorie intake will be measured. Total energy intake will be measured from t = 0 until t = 20 minutes or as soon as the as the subject stops eating for more than 5 minutes.
Secondary Effects on GI hormone response - GLP-1 Plasma GLP-1 will be measured with a commercially available immunoassay kit (MILLIPLEX® MAP; Millipore Corporation, Billerica, MA, USA). Blood will be drawn at the following time points: t = -16, t = -1 (before the administration of the pre-load), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-load).
Secondary Effects on GI hormone response - PYY Plasma PYY will be measured with a commercially available immunoassay kit (MILLIPLEX® MAP; Millipore Corporation, Billerica, MA, USA). Blood will be drawn at the following time points :t = -16, t = -1 (before the administration of the pre-load), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-load).
Secondary Effects on GI hormone response - CCK Plasma cholecystokinin (CCK) levels will be measured with a sensitive radioimmunoassay using a highly specific antiserum. Blood will be drawn at the following time points: t = -16, t = -1 (before the administration of the pre-load), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-load).
Secondary Effects on GI hormone response - ghrelin Plasma ghrelin will be measured with a commercially available immunoassay kit (MILLIPLEX® MAP; Millipore Corporation, Billerica, MA, USA). Blood will be drawn at the following time points: t = -16, t = -1 (before the administration of the pre-load), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-load).
Secondary Effects on glycemic control - plasma glucose Blood glucose concentrations will be measured by a commercial hexokinase-glucose-6-phosphate-dehydrogenase method (Roche, Basel, Switzerland). Blood will be drawn at the following time points: t = -16, t = -1 (before administration of the pre-load), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-load).
Secondary Effects on glycemic control - plasma insulin Insulin will be measured with a commercially available immunoassay kit (MILLIPLEX® MAP; Millipore Corporation, Billerica, MA, USA). The lowest level of insulin that can be detected by this assay is 87 pg/mL when using a 25 µL sample. The intra-assay coefficient of variation for insulin is below 10%, whereas the inter-assay coefficient of variation is below 15%. Blood will be drawn at the following time points: t = -16, t = -1 (before the administration of the pre-load), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-load).
Secondary Effects on glycemic control - plasma c-peptide C-peptide will be measured with a commercially available immunoassay kit (MILLIPLEX® MAP; Millipore Corporation, Billerica, MA, USA). The lowest level of c-peptide that can be detected by this assay is 9.5 pg/mL when using a 25 µL sample. The intra-assay coefficient of variation for c-peptide is below 10%, whereas the inter-assay coefficient of variation is below 15%. Blood will be drawn at the following time points: t = -16, t = -1 (before administration of the pre-load), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-load).
Secondary Effects on glycemic control - plasma glucagon Glucagon will be measured with a commercially available immunoassay kit (MILLIPLEX® MAP; Millipore Corporation, Billerica, MA, USA). The lowest level of glucagon that can be detected by this assay is 13 pg/mL when using a 25 µL sample. The intra-assay coefficient of variation for glucagon is below 10%, whereas the inter-assay coefficient of variation is below 15%. Blood will be drawn at the following time points: t = -16, t = -1 (before the administration of the pre-load), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-load).
Secondary Effects on appetite-related sensations Appetite perceptions (feelings of: a) hunger, b) satiety) are assessed by visual analogue scale (VAS). Visual analogue scales consist of a horizontal, unstructured, 10-cm line representing the minimum (0.0 points) to the maximum rating (10.0 points). Subjects assign a vertical mark across the line to indicate the magnitude of their subjective sensation at the present time point. The measurement is quantified by the distance from the left end of the line (minimum rating) to the subject's vertical mark. Visual analogue scales will be recorded at the following time points: t = -16, t = -1 (before the administration of the pre-loads), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-loads).
Secondary Effects on GI tolerance GI symptoms will be assessed by use of a checklist including the following questions: abdominal pain, nausea, vomiting, diarrhoea, borborygmi, abdominal distension, eructation and increased flatus. GI tolerance will be recorded at t = -16, -1 (before the administration of the pre-load), 30, 60, 120 and 180 minutes (after the administration of the pre-load).
Secondary Sweetness of pre-load Sweetness is assessed by gLMS. General Labeled Magnitude Scales consist of an unequal, vertical line, which is marked with quasi-logarithmic verbal anchors describing different intensities (e.g. "strongest imaginable", "barely detectable"). Participants are instructed to place a mark on the line where their perceived intensity of sensation lies. Sweetness of the pre-load will be recorded at t = -10 minutes.
Secondary Liking ot the pre-load Liking is assessed by gLMS. General Labeled Magnitude Scales consist of an unequal, vertical line, which is marked with quasi-logarithmic verbal anchors describing different intensities (e.g. "strongest imaginable", "barely detectable"). Participants are instructed to place a mark on the line where their perceived intensity of sensation lies. Liking of the pre-load will be recorded at t = -10 minutes.
Secondary Liking of the test meal Liking is assessed by gLMS. General Labeled Magnitude Scales consist of an unequal, vertical line, which is marked with quasi-logarithmic verbal anchors describing different intensities (e.g. "strongest imaginable", "barely detectable"). Participants are instructed to place a mark on the line where their perceived intensity of sensation lies. Liking of the test meal will be recorded at t = 180 minutes.
See also
  Status Clinical Trial Phase
Completed NCT04219189 - The Acute Effect of Vaping on Food Intake N/A
Completed NCT02957318 - Effect of Potato Fiber on Appetite and Fecal Fat Excretion N/A
Completed NCT04378374 - The Effect of Pulse Flours on Blood Glucose, Satiety and Food Intake N/A
Completed NCT01199770 - Pasta Formulations, Portion Sizes and Their Effect on Appetite N/A
Recruiting NCT05443347 - Activity, Adiposity, and Appetite in Adolescents 2 Intervention N/A
Withdrawn NCT02111486 - Effect of Certain Breakfasts on Appetite Control N/A
Completed NCT02379312 - Comparison of the Satiety Effect of a Very Low Energy Foam With Normal Energy Foams N/A
Completed NCT03697486 - The Effect of Breakfast With Different Macronutrient Composition on PYY, Ghrelin, GLP-1,Glucose Level, VAS for Hunger, VAS for Satiety and Ad Libitum Intake 4 Hours After Breakfast in Obese Women N/A
Completed NCT01222845 - Glycaemic, Insulinaemic and Appetite Responses to Two Different Types of Porridge N/A
Completed NCT03701503 - The Comparison of PYY, Ghrelin, GLP1, Glucose Level, Level of Satiety, and Ad Libitum Intake in Obese and Non-Obese Patients After Breakfast With Balanced Macronutrient Composition N/A
Completed NCT03900130 - The Omnibus Satiety Metric: Predicting Satiety in Humans Through Brain, Blood, and Subjective Data N/A
Completed NCT05012046 - Effect of 100% Orange Juice on Food Intake and Glycemic Response in Adults N/A
Completed NCT02484625 - The Effect of Dairy and Non-Dairy Snacks on Food Intake, Subjective Appetite in Children N/A
Withdrawn NCT01246492 - The Effect of Artificial Sweeteners on Blood Glucose Response N/A
Completed NCT05534152 - Effect of Sumac on Appetite and Food Intake N/A
Completed NCT03974165 - Cereal-based Products Fortified With Legumes and Effects on Glycemic Control and Appetite Regulation N/A
Completed NCT01592149 - Survey of Prevalence of Loss of Appetite in Subject With Health Disorders N/A
Recruiting NCT01121783 - The Effect of Lactisole on the Responses to Glucose Solution N/A
Completed NCT01102907 - Effect of Food Form on Satiety and Gastric Emptying
Completed NCT03128684 - The Effects of Lentil-containing Food Products on Satiety and Food Intake N/A